OSE Immunotherapeutics, a clinical-stage biotechnology company focused on developing and partnering therapies to control the immune system for immuno-oncology and autoimmune diseases and deep technology innovative start-up MAbSilico have agreed to use artificial intelligence (AI)-based solutions for the development of therapeutic antibody-drug conjugates.
As part of the agreement, OSE Immunotherapeutics plans to incorporate innovative problem-solving solutions like AI for the development of new monoclonal antibodies. As such, the agreement capitalizes on artificial intelligence and deep learning to develop therapeutic monoclonal antibodies, including novel bispecific antibodies (BiCKI® platform)
MAbSilico’s technology solutions have already been tested and validated by OSE Immunotherapeutics and the company has agreed to use this technology in six antibody programs, including novel bispecific antibodies. The collaboration is expected to run for 3 years.
Drug discovery, especially cancer research and discovery, is a multidimensional problem requiring diverse types of datasets. The advent of Artificial Intelligence (AI) means that automation has become a major part of modern drug discovery. This has resulted in increased speed and accuracy in drug discovery and evaluation of the safety, pharmacokinetics, and efficacy of potential candidate compounds while, at the same time, allowing novel ways of drug design and synthesis.
In addition, the use of AI and numerical simulation can guide therapeutic antibody discovery, help reduce the risk of failure and accelerate the pre-clinical development process of these drug candidates before clinical tests.
“We are delighted with this collaboration, we constantly strive to introduce innovative technologies to develop first-in-class products in immuno-oncology and autoimmune diseases,” noted Nicolas Poirier, Chief Scientific Officer of OSE Immunotherapeutics.
“Due to the devastating nature of these diseases, our development strategies need to be accelerated and artificial intelligence solutions for drug discovery offered by MAbSilico can be a great asset to achieve this goal,” he added.
”While all MAbSilico’s commercialized solutions are included in this three-year agreement, OSE Immunotherapeuticsalso gains early access to MAbSilico’s SaaS (Software as a Service) and technologies in development including those for the conception of therapeutic antibodies optimized for bioproduction. OSE provides internal data to MAbSilico in order to feed their algorithms in development and deliver new technology faster,” Poirier noted.
“It is a pleasure to start this collaboration with one of the top French Biotech. This partnership demonstrates the need to fasten new AI-based solutions for antibody-drug discovery. We believe that with the trust and collaboration of OSE, we will accelerate the release of our software and new technologies,” Vincent Puard, Chief Executive Officer of MAbSilico, concluded.